Exhibit 99.2 Q1 2024 Results Conference Call April 30, 2024

Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: • Future sales or sales growth; • Estimates of potential market size and demand for the Company’s current and future products; • Plans for expansion outside of the U.S.; • The effectiveness of amniotic tissue as a therapy for any particular indication or condition; • Expected spending on research and development and litigation; • Expectations regarding the reimbursement environment for the Company’s products; • The Company’s long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability 2

Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: • Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors; • The future market for the Company’s products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company’s products, market acceptance of the Company’s products, and adequate reimbursement for such therapies; • The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; and • The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward- looking statement. 3

Joe Capper Chief Executive Officer helping humans heal.

Q1:24 Highlights 1 Gross Margin Net Income Net Sales Adjusted EBITDA $85MM 85% $9MM $19MM +18% year-over-year 22% of net sales Cash Balance Portfolio Expansion Free Cash Flow Launched $48MM into Xenografts $5MM E-Commerce & Account Management Platform 1 – EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non-GAAP financial measures. See our Earnings Release for the quarter ended March 31, 2024 for a 5 reconciliation to the nearest GAAP measure.

Evolving Our Strategic Priorities from 2023 to 2024 2023 2024 Innovate & diversify product portfolio to Build leadership position in Wound & Surgical maximize growth Develop & deploy programs to expand Develop opportunities in adjacent markets footprint in Surgical market Demonstrate corporate discipline around expenses Introduce initiatives to enhance customer intimacy Committed to Evolving & Achieving Strategic Priorities to Strengthen and Grow Business Over Long-Term 6

AXIOFILL Update FDA has taken position that AXIOFILL is subject to regulation under Section 351 as a biologic drug MIMEDX pursued formal pre-RFD and RFD process in 2023 Currently, similar human-derived particulate products are on the market and classified either as Section 361 products or with FDA 510(k) clearance In March following RFD outcome, we filed a claim in federal court; expect this matter to take a year or less at a cost estimated to be in the six figures Believe outcome of this proceeding is important for our industry and product pipeline 7

Doug Rice Chief Financial Officer helping humans heal.

Strong Q1:24 Net Sales Total Net Sales By Site of Service By Product Type $85 Other $11MM $72 $28 +32% $26 Hospital Private $44MM Office +4% $57 $30MM $45 +41% Q1:23 Q1:24 Q1:23 Q1:24 Wound Surgical Sixth consecutive quarter of double-digit year-over-year net sales growth 9 $ millions $ millions

Q1:24 Gross Profit & Gross Margin Favorable Mix Once Again Helping Drive Gross Margin Expansion 80 $72 Q1:24 gross profit and gross margin $59 improvements were driven by higher net sales and a favorable product mix, respectively 85% 83% Continue to expect this business to achieve consistent, mid-80% gross margins 0 Q1:23 Q1:24 10 $ millions Gross Margin

Q1:24 Operating Expenses Q1:23 $55 $52 Q1:24 Operating expense leverage more than offsetting higher sales $3 $3 commissions % of net sales 73% 65% 5% 3% R&D SG&A Adjusted EBITDA $19 margin above 20% $9 $6 to start 2024 -$5 8% % of net sales (7%) 11% 22% Adjusted EBITDA Net Income/Loss 11 $ millions $ millions

Q1:24 Balance Sheet & Cash Flows Q1:24 Q1:24 Revolving Credit Refinancing Free Cash Flow Line Repaid Net Cash Balance Completed $29MM $5MM $30MM Jan. 2024 Strengthening Financial Position Provides Optionality for Future Organic and Inorganic Opportunities 12

Joe Capper Chief Executive Officer helping humans heal.

Q1:24 Summary Net Sales of $85 million were up 18% year-over-year Gross profit margin increased to 85% Adjusted EBITDA of $19 million reflected 22% of net sales Growth in all sites-of-service Successful refinancing in January to strengthen our balance sheet Acquired rights to commercialize our first xenograft product later this year 14

Medicare Addressing Needed Changes for Skin Substitute Reimbursement Last week, a unified proposed LCD was published outlining a significant overhaul of Medicare reimbursement of skin substitutes Similar in some ways to LCDs from last year that were ultimately shelved, with some important differences If finalized as proposed, EPIFIX and EPICORD would reflect two of the 15 products eligible for coverage in the category EPIEFFECT is among those not covered; we had planned to invest in studies and will seek clarity on specific evidence generation needed in order to ultimately obtain coverage for this product Uncertain timing for finalization, but likely some time in 2H:24 Near-term uncertainty likely in the marketplace, but longer-term a positive outcome for MIMEDX if implemented as written 15

Closing Remarks, Q&A

Exhibit 99.3 Investor Presentation May 2024 helping humans heal.

Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding: • Future sales or sales growth; • Estimates of potential market size and demand for the Company’s current and future products; • Plans for expansion outside of the U.S.; • The effectiveness of amniotic tissue as a therapy for any particular indication or condition; • Expected spending on research and development and litigation; • Expectations regarding the reimbursement environment for the Company’s products; • The Company’s long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability 2

Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: • Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors; • The future market for the Company’s products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company’s products, market acceptance of the Company’s products, and adequate reimbursement for such therapies; • The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming; and • The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward- looking statement. 3

MIMEDX: Focused on Global Leadership in Healing Solutions Helping To be the leading global provider of Our Why Our healing solutions through relentless Humans Statement Vision innovation to restore quality of life. Heal Unparalleled Expertise Relentless Innovation Increasing Patient Access 15 >15 Years Dedicated to #1 Amniotic New Product Launches Unmatched Clinical Over 300 Million Targeted International Innovation in Wound Care Skin Substitute* Creating New Opportunities & Scientific Evidence Payer Covered Lives Expansion for Growth 4 *BiomedGPS – SmartTRAK. 2022 US Amniotic Tissue Market – Revenue Shares. https://www.smarttrak.com. Accessed April 13, 2023.

The Unmet Need for Healing Solutions Is Large and Growing million people are estimated to suffer from chronic, non-healing 7 1 wounds in the U.S. • Aging population • Obesity Favorable • Smoking history • Heart & vascular disease Demographic Trends • Diabetes • Millions of surgical procedures annually Ineffective Wound It is estimated that up to 85% of amputations are avoidable with a Management Leads holistic multispecialty team approach that incorporates innovative 2 to Poor Outcomes treatments and adherence to treatment parameters. Advances in Management Driving When applied following parameters for use, patients treated with EPIFIX 2 Improved Outcomes experienced reductions in major amputations and hospital utilization. for Patients 1. Wound Care Awareness. Healogics. Accessed October 19, 2023. https://www.healogics.com/wound-care-awareness/ 2. Tettelbach WH, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic 5 ulcer treatment. J Wound Care. 2022 Feb 1;31(Sup2):S10-S31.

Patient Journeys in Wound & Surgical Meeting patients in settings where they receive care to drive continued adoption of MIMEDX’s products Wound Types Sites-of-Service Complex/Dehisced Hospital Inpatient Wounds Chronic Wounds Wound Care Centers Surgical Acute Wounds Private Office 6 S ever i t y

Expanding Breadth of Skin Substitutes Leading Human-Derived Portfolio Best-in-Class Wound Product Portfolio Innovative Offering for Surgical Market Emerging Xenograft Portfolio Announced exclusive manufacturing and supply agreement with Regenity Biosciences, a leading global developer and manufacturer of bioresorbable technologies. Provides MIMEDX with a bovine-derived collagen matrix particulate product that is 510(k)-cleared by the FDA and is indicated for the management of exudating wounds and to control minor bleeding. Builds on our strategic goal to augment our growth through strategic portfolio expansion, which can nearly double our addressable market opportunity in the Wound & Surgical markets we serve. 7

Sizable, Expanding Opportunities in Wound & Surgical Markets CAGRs* Total Addressable Markets +5% $4.9B +7% $0.7B $3.9B $0.5B +3% $2.5B $2.1B +7% $1.8B $321MM $1.3B MIMEDX 2023 Net Sales 2023 2028E U.S. Wound U.S. Surgical Japan Introduction of Xenografts for Surgical Applications Meaningfully Grows our Total Addressable Market *CAGRs are the estimated cumulative annual growth rates for the period January 1, 2023 through December 31, 2028 8 Market data sources include: BioMed GPS SmartTrak; 3rd party proprietary assessment; Management estimates

Large Placental Donation Network & Proprietary Tissue Processing Technology Placental Donation Network Proprietary Processing 5 1 2 3 4 6 7 Expectant Mom Mom Consents to Delivery of Healthy Donated Placental Microbiological Proprietary Shelf-stable Introduced to Donate and Completes Baby via Tissues Recovered Testing of Donor Processing and Packaged Donation Program FDA Donor Screening Caesarean Section Tissue Terminal Sterilization Product Assessment in the US 110,000+ Over 3 million Placentas recovered to-date via network of contracted birthing Allografts distributed to-date hospitals and dedicated team of donor recovery specialists 9

Diversified Business Across Multiple Sites of Service Site of Segment Commentary Service Hospital Setting Stable reimbursement (Inpatient & settings and growing with Outpatient) & expanded use of products in Wound Care surgical applications Clinics Medicare reimbursement evolving, resulting in Private Office opportunity for EPIFIX & EPICORD Derived from other sites of Other service, including federal facilities and international 10 *Sales mix based upon trailing twelve months net sales ending March 31, 2024

Physician Office Medicare Reimbursement Overhaul Underway Led to an increase in skin substitutes With a significant number of these Scrutiny of excessive Medicare Allowed Resulting in a de-facto 3 1 2 on the Medicare ASP List Charges for skin substitutes under WAC products priced above $500/sq. cm national coverage proposal $1,750,000,000 80 $2,000 Average Price of Skin Substitutes on ASP List $1,500,000,000 70 Has Increased More Than 60 Threefold Since Q1:22 $1,500 $1,250,000,000 50 $1,000,000,000 40 4 $1,000 LCDs proposed in April $750,000,000 2024 would disallow 30 coverage of ~180 products $500,000,000 in the category 20 $500 $250,000,000 10 EPIFIX and EPICORD are $0 0 $0 among the 15 covered 2019 2022 Q1:22 Q2:24 Q1:22 Q2:24 products eligible for Skin Substitute Products on ASP List reimbursement in the Price per sq. cm on ASP List Skin Substitute Products on ASP List Skin Substitute Products Previously NOT on ASP List proposal Recent Proposed LCDs Reflect Unified National Approach to Curb Abuses in Private Office 1) https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Part-B-National-Summary-Data-File/Overview; Accessed: December 15, 2023. 2) WAC refers to “Wholesale Acquisition Cost” 3) ASP List refers to the Medicare Part B ASP Drug Pricing Files and CMS refers to the Centers for Medicare and Medicaid Services, Data Source: ASP Pricing Files. Centers for Medicare & Medicaid Services. Accessed March 18, 2024. 11 https://www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files 4) LCDs refer to “Local Coverage Determination”

Our Strategic Priorities • Continue momentum with new organic products in Wound & Surgical Innovate & Diversify Build leadership position Product Portfolio to • Consider additional inorganic additions in Wound & Surgical Maximize Growth to our product offering • Drive further uptake of EPIFIX in Japan • Increase our presence in targeted Develop & Deploy surgical settings with our portfolio Programs to Expand • Invest in clinical data, partnering with Footprint in Surgical KOLs • Execute on initiatives to increase Enhance Customer customer “stickiness” and reduce Intimacy churn helping humans heal. 12

Q1:24 Highlights 1 Net Income Net Sales Gross Margin Adjusted EBITDA $9MM $85MM 85% $19MM +18% year-over-year 22% of net sales Portfolio Expansion Free Cash Flow Cash Balance Launched into Xenografts $5MM $48MM E-Commerce & Account Management Platform 1 – EBITDA, Adjusted EBITDA, related margins and Free Cash Flow are non-GAAP financial measures. See our Earnings Release for the quarter ended March 31, 2024 for a 13 reconciliation to the nearest GAAP measure.

Management Team with Track Record of Success in MedTech Doug Rice Joe Capper Ricci Whitlow John Harper, Ph.D. Kim Moller Eric Smith Butch Hulse Kate Surdez Matt Notarianni Chief Financial Chief Executive Chief Operating Chief Scientific Officer & SVP, Sales SVP, Marketing & Chief Administrative Chief Human Head of IR Officer Officer Officer SVP, R&D International Officer & General Counsel Resource Officer Prior Roles Include: 14

Conclusion Pioneer and Expanding Large and Committed to leader in pipeline in growing delivering above- Advanced Wound Wound & market market growth Care Surgical opportunities and profitability helping humans heal. 15